Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting

AIDS

Volumn 15, Issue 3, 2001, Pages 309-320

  Miller, V ^a   Vandamme, A M ^a   Loveday, C ^a   Staszewski, S ^a   Lundgren, J ^a   Youle, M ^a   Ait Khaled, M ^a   Boucher, C ^a   Brun Vezinet F ^a   Dedes, N ^a   Giaquinto, C ^a   Hertogs, K ^a   Houyez, F ^a   Perrin, L ^a   Pillay, D ^a   Schmit, J C ^a   Schuurman, R ^a   Lange, J ^a   Bahegyi D ^a   Biondi, G ^a   Broekhuizen, A ^a   Bush Donovan, C ^a   Camacho, R ^a   Carlier, H ^a   Clavel, F ^a   Clotet, B ^a   Clumeck, N ^a   Colebunders, R ^a   De Clerq, K ^a   De Jaegher, J J ^a   De Schrijver, G ^a   De Smet, K ^a   Hall, W ^a   Harrigan, R ^a   Hatzakis, A ^a   Hellmann, N ^a   Hoetelmans, R ^a   Holtzer, C ^a   Katlama, C ^a   Larder, B ^a   Loriaux, E ^a   McCreedy, B ^a   Mulcahy, F ^a   Opravil, M ^a   Phillips, A ^a   Ruiz, N ^a   Shulse, E ^a   Sonnerborg A ^a   Soriano, V ^a   Steel, H ^a   Vella, S ^a   Williams, A ^a   more..

^a EuroGuidelines Grp HIV Resistance   (Netherlands)

Author keywords

Antiretroviral therapy; Drug resistance; Genotype; HIV 1 drug susceptibility; Phonotype; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

DRUG SENSITIVITY; EUROPE; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; LABORATORIES; QUALITY ASSURANCE, HEALTH CARE;

EID: 0035895674     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102160-00003     Document Type: Review

References (119)

1. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
2. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
3. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
4. Dual resistance to zidovudine (ZDV) and lamivudine (3TC) in patients treated with ZDV/3TC combination therapy: Association with therapy failure
5. HIV-1 genotype resistance patterns predict response to saguinavir/ritonavir therapy in patients in whom previous protease inhibitor therapy has failed
6. Novel four-drug salvage treatment regimens after failure of a human immuno-deficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
7. Retrospective analysis of baseline susceptibility to adefovir dipivoxil is predictive of virological response in GS-96-408
8. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
9. HIV-1 Baseline genotype/phenotype and virological response following salvage therapy with Ziagen (abacavir ABC), amprenavir (APV), and Sustiva (efavirenz, EFV)
10. Impact of drug resistance mutations on virologic response to salvage therapy
11. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to a protease inhibitors predicts outcome of therapy
12. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
13. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV Cohort
14. Baseline HIV-1 genotypic resistance to a newly added nucleoside analogue is predictive for virologic failure of the new therapy
15. The relationship between baseline HIV drug resistance and response To antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
16. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
17. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
18. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA3001)
19. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL,ANRS 088)
20. Testing for HIV-1 drug resistance: New developments and clinical implications. Recent resource developments
21. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
22. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
23. Most HIV-1 genetic subtypes have entered Sweden
24. Presence of multiple HIV subtypes and a high frequency of subtype chimeric viruses in heterosexually infected women
25. Genotyping and phenotyping analysis of B and Non-B HIV-1 subtypes from patients under HAART
26. High frequency of non-B subtypes in newly diagnosed HIV-infections in Switzerland
27. HIV-1 subtypes: Implications for epidemiology, pathogenicity, vaccines and diagnostics
28. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with Group O strains of human immuno-deficiency virus type 1
29. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil
30. Pol gene diversity of five human immunodeficiency virus type 1 sub-types: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
31. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
32. Second Spanish consensus on the use of drug resistance testing in clinical practice
33. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
34. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
35. HIV drug resistance in newly infected individuals
36. Transmission of antiretroviral-drug-resistant HIV-1 variants
37. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
38. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatmentnaive patients
39. Prevalence of genotypic and phenotypic resistance to anti-retrovira drugs in a cohort of therapy-naive HIV-1 infected US military personnel
40. Detection of drug resistance associated mutations in HIV primary infection within the UK
41. Prevalence of resistance mutations in antiretroviral-naive patients: French National Study
42. Prevalence of resistance-associated mutations in patients starting antivirals: Virological response after approximately 1 year of therapy
43. Prevalence of baseline drug resistance mutations in primary HIV infection patients from the QUEST study
44. Trends in prevalence of primary HIV-1 drug resistance among recently infected persons in San Francisco
45. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1 seroconverters in the USA, 1993-1998
46. High prevalence of genotypic changes in antiretroviral drug-naive patients in the UK
47. Prevalence of HIV-1 drug resistance mutations in naive patients in Belgian hospitals
48. HIV-1 transmission by a needle-stick injury despite rapid initiation of four-drug postexposure prophylaxis
49. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors
50. Vertical transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors
51. Transmission of human immunodeflclency virus type 1 resistant to nevirapine and zidovudine
52. Selective vertical transmission of HIV-1 antlretroviral resistance mutations
53. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation
54. Protease inhlbitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
55. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
56. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
57. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
58. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
59. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after disontinuation of in vitro lamivudine drug pressure
60. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir
61. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
62. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
63. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure
64. Mega-HAART, resistance and drug holidays
65. Patterns of resistance and cross-resistance to HIV-1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor Ioviride
66. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants
67. Establishment of new transmissible and drug-sensitive HIV-1 wild-types due to transmission of nucleoslde analogue resistant virus
68. Low levels of preexisting mutant virus blunts HIV-1 response to therapy
69. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure
70. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus
71. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-rltonavir: Genotyplc analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315
72. Gilbert P for the ACTG244/RV79 Study Team T215Y mutation associated with zidovudine (ZDV) resistance leads to poor response to ZDV+ddI or ZDV+ ddI+NVP ACTG244/RV79
73. Baseline HIV-1 protease and reverse transcriptase genotype as a predictor of response to ZDV+3TC+Indinavir
74. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
75. Mutations at codons 10 and 36 of protease region in absence of primary mutations may correlate with virological outcome in naive patients starting a PI-containing HAART regimen
76. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006)
77. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
78. Prevalence of drug resistance mutations in patients with primary HIV-1 infection
79. Vigorous HIV-1 specific CD4+ T cell responses assocaited with control of viremia
80. Prevalence of phenotyplc and genotypic resistance in recently infected, antiretroviral inexperienced patients: The German HIV-research initiative cohort
81. Prevalence of genotyplc resistance to nucleoslde analogues and protease inhibltors in Spain: A multlcenter cross-sectional study (ERASE-2)
82. HIV-1 reverse transcriptase (RT) genotype and viral sensitivity to RT inhibitors during abacavir monotherapy and after switch to zidovudine, lamivudine and abacavir HAART
83. Documentation of HIV-1 superinfection and acceleration of disease progression
84. Substantial correlation between HIV-1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in heavily treated patients
85. CDC public health service guidelines for the management of healthcare worker exposures to HIV and recommendations for post exposure prophylaxis
86. Postexposure chemoprophylaxis for occupational exposures to human immunodeficiency virus
87. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
88. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
89. Modulation of P-glycoprotein function in human lymphocytes and caco-2 cell monolayers by HIV-1 proteas inhibitors
90. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
91. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
92. Estimates of the number of patients highly exposed to antiretroviral therapy with severe biological failure
93. Potential for antiretroviral resistance in Europe: Results from the EuroSIDA Study
94. Phenotypic testing predicts response in successive protease inhibitor-based regimen
95. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy in heavily experienced patients
96. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
97. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only
98. Prior treatment with mono or dual NRTI's before HAART as predictor of virological failure in simplified abacavir-based triple NRTI regimens: Results from the Simplified Maintenance Trial (SMT) and CNA30017
99. Response to abacavir-containing regimens is not affected by presence of pre-existing lamivudine resistance and is greater than response in nonabacavir-containing regimens in VIRA3001
100. Does the M184V mutation affect the efficacy of HAART? Evidence from sequential addition of protease inhibitors or abacavir to zidovudine/lamivudine or stavudine/lamivudine
101. Development of amprenavir resistance in NRTI-experienced patients: Alternative mechanisms and correlation with baseline resistance to concomitant NRTIs
102. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
103. Virological and clinical response to second line protease inhibitor-containing regimens
104. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both an initial and salvage therapy
105. Resistance and response to PI-treatment in RTI and PI-experienced patients: The Euro-SIDA Cohort Study
106. Multi-drug rescue therapy (MDRT)in three cohorts of HIV-positive individuals
107. Ritonavir intensification of indinavir-containing antiretroviral regimens: The effect of increasing indinavir trough concentration and protease resistance on virological response
108. Identification of clinically relevant phenotypic and genotypic break-points for ABT-378/r in multiple PI-experienced, NNRTI-naive patients
109. Viral load and disease progression in infants infected with human immunodeficiency virus type 1
110. HIV-I Viral load and CD4 count in untreated children with Vertically acquired mild or asymptomatic disease - PENTA I Virology
111. A randomised double-blind trial of the addition of lamuvidine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: The PENTA-4 trial
112. Plasma viral load and genotypic resistance patterns in children adding lamivudine to current reverse transcriptase inhibitor therapy (PENTA-4 trial)
113. A case/control study evaluating viral resistance in paediatric patients enrolled in PACTG 15
114. Genotypic antiretroviral resistance monitoring in a recent cohort of HIV-infected pregnant women from New York City
115. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
116. Mutations in retroviral genes associated with drug resistance: 1999-2000 update
117. Public health implications of antiretroviral therapy and HIV drug resistance
118. Standardization and quality assurance for antimicrobial resistance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS)